Answers are grounded in this paper and cite their sources.
Case report demonstrates acute renal failure and myocarditis following nonsucrose intravenous immunoglobulin therapy in thrombocytopenia, highlighting potential organ toxicity.
Letters19 August 2003Acute Renal Failure and Myocarditis Associated with Intravenous Immunoglobulin TherapyIrme Akhtar, MD and Bahar Bastani, MDIrme Akhtar, MDSaint Louis University School of Medicine; St. Louis, MO 63110 (Akhtar, Bastani)Search for more papers by this author and Bahar Bastani, MDSaint Louis University School of Medicine; St. Louis, MO 63110 (Akhtar, Bastani)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-4-200308190-00025-w3 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Intravenous immunoglobulin (IVIG) is a widely used treatment for various autoimmune disorders. Acute renal failure, although rare, is a known complication of this therapy; in most reports, it has occurred after administration of IVIG preparations containing sucrose as a stabilizing agent. We report a case of acute renal failure in a patient receiving a nonsucrose preparation of IVIG.Case Report: A 59-year-old woman with a history of hypertension and chronic idiopathic thrombocytopenic purpura presented with persistent severe thrombocytopenia that was resistant to standard medical therapy. She was taking danazol, metoprolol, ramipril, calcium carbonate, and alendronate. On ...References1. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. 1997;8:1788-94. [PMID: 9355083] CrossrefMedlineGoogle Scholar2. Epstein JS, Zoon KC. Letter to Healthcare ProvidersImportant Drug Warning: Immune Globulin Intravenous (Human). Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 13 November 1998. Available at www.fda.gov/cber/ltr/igiv111398.htm. Google Scholar3. Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. QJM. 2000;93:751-5. [PMID: 11077032] CrossrefMedlineGoogle Scholar4. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol. 1997;13:775-7. [PMID: 9284845] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Saint Louis University School of Medicine; St. Louis, MO 63110 (Akhtar, Bastani) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunoglobulinsANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONSRisque thrombogène des immunoglobulines intraveineuses: mythe ou réalité?Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literatureIntravenous immunoglobulin-associated cranial pachymeningitisBlood, blood components, plasma, and plasma products 19 August 2003Volume 139, Issue 4Page: W-65KeywordsAcute renal failureAttentionCreatinineGlucoseGlycineIntravenous immunoglobulinMyocarditisPlateletsSucroseTroponin ePublished: 19 August 2003 Issue Published: 19 August 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Akhtar et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: